Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meera R Chappidi

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The Journal of Sexual Medicine|July 16, 2017
Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive FactorsFilippo Pederzoli, Meera R Chappidi, Sarah Collica, et al.
Urology|January 21, 2017
Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder CancerMeera R Chappidi, Max Kates, Aaron Brant, et al.
JNCI Cancer Spectrum|November 5, 2021
Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC StudyMichael T Marrone, Alison M Mondul, Anna E Prizment, et al.
BJU International|May 9, 2017
Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidanceJeffrey J Tosoian, Meera R Chappidi, Jay T Bishoff, et al.
BJU International|June 14, 2018
Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?Gregory A Joice, Meera R Chappidi, Hiten D Patel, et al.
Urologic Oncology|October 25, 2016
Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomyMeera R Chappidi, Heather J Chalfin, Daniel J Johnson, et al.
Urologic Oncology|February 23, 2016
Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomyMeera R Chappidi, Max Kates, Hiten D Patel, et al.
Urologic Oncology|September 19, 2016
Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?Aaron Brant, Max Kates, Meera R Chappidi, et al.
The Journal of Urology|January 4, 2022
The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate CancerMeera R Chappidi, Alexander Bell, Janet E Cowan, et al.
The Journal of Urology|September 6, 2022
Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional CohortKevin Shee, Samuel L Washington, Janet E Cowan, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The Journal of Sexual Medicine|July 16, 2017
Analysis of Hospital Readmissions After Prosthetic Urologic Surgery in the United States: Nationally Representative Estimates of Causes, Costs, and Predictive FactorsFilippo Pederzoli, Meera R Chappidi, Sarah Collica, et al.
Urology|January 21, 2017
Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder CancerMeera R Chappidi, Max Kates, Aaron Brant, et al.
JNCI Cancer Spectrum|November 5, 2021
Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC StudyMichael T Marrone, Alison M Mondul, Anna E Prizment, et al.
BJU International|May 9, 2017
Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidanceJeffrey J Tosoian, Meera R Chappidi, Jay T Bishoff, et al.
BJU International|June 14, 2018
Hospitalisation and readmission costs after radical cystectomy in a nationally representative sample: does urinary reconstruction matter?Gregory A Joice, Meera R Chappidi, Hiten D Patel, et al.
Urologic Oncology|October 25, 2016
Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomyMeera R Chappidi, Heather J Chalfin, Daniel J Johnson, et al.
Urologic Oncology|February 23, 2016
Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomyMeera R Chappidi, Max Kates, Hiten D Patel, et al.
Urologic Oncology|September 19, 2016
Pathologic response in patients receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer: Is therapeutic effect owing to chemotherapy or TURBT?Aaron Brant, Max Kates, Meera R Chappidi, et al.
The Journal of Urology|January 4, 2022
The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate CancerMeera R Chappidi, Alexander Bell, Janet E Cowan, et al.
The Journal of Urology|September 6, 2022
Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional CohortKevin Shee, Samuel L Washington, Janet E Cowan, et al.
Pageof 4